Phaseline

Targets › GPX3

GPX3 (Glutathione peroxidase 3): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Other; next expected readout Dec 2026.

Protects cells and enzymes from oxidative damage, by catalyzing the reduction of hydrogen peroxide, lipid peroxides and organic hydroperoxide, by glutathione. (UniProt, P22352)

Open in Phaseline: the race on GPX3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sound PharmaceuticalsEbselen (SPI-1005)
Glutathione peroxidase mimetic
GPX1, GPX2, GPX3, GPX4Phase 3Meniere's Disease; Hearing LossDec 2026

Conditions

Meniere's Disease (1) Hearing Loss (1)

Modalities

small molecule (1)

Companies

Sound Pharmaceuticals (1)

Related targets

GPX1 (1) GPX2 (1) GPX4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.